Arrowhead Pharmaceuticals (NASDAQ:ARWR) Releases Earnings Results, Misses Expectations By $0.13 EPS

Posted by Brenda Bartman on Aug 4th, 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13), FiscalAI reports. The company had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.Arrowhead Pharmaceuticals’s revenue was up 171.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.26) earnings per share.

Here are the key takeaways from Arrowhead Pharmaceuticals’ conference call:

Phase III SHASTA-3 and SHASTA-4 both met all primary and prespecified secondary endpoints, with median triglyceride reductions of 79% and 81% and a 78% reduction in pooled acute pancreatitis events versus placebo. Arrowhead reported a 100% reduction in events among the highest-risk subgroup, though detailed data remain subject to the upcoming ESC presentation.
REDEMPLO’s U.S. FCS launch continued to gain traction, with prescriptions more than doubling sequentially, over 400 unique prescribers, and approximately $2.4 million in quarterly commercial revenue. The company also reported approvals in Australia and the European Union, expanding its approved footprint to five geographies.
Arrowhead acquired a priority review voucher for $215 million, which it expects could shorten FDA review of the planned SHTG supplemental NDA from 10 months to six months. The company plans to submit the sNDA by the end of 2026 and is preparing to expand its field organization from about 5,000 to more than 20,000 healthcare-provider targets.
The pipeline has several potential catalysts, including September data for ARO-DIMER-PA and the ARO-MAPT CNS delivery program, plus fourth-quarter updates for ARO-INHBE and ARO-ALK7. Management expects 23 candidates in clinical trials by year-end, but most programs remain early-stage and carry substantial development risk.
Arrowhead’s quarterly net loss widened to $194.3 million from $175.2 million year over year, while operating expenses rose to approximately $245 million as R&D and commercialization investments increased. The company held about $1.6 billion in cash and investments, but expects continued spending on clinical development, regulatory work, manufacturing, and potential SHTG launch preparation.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR traded up $3.58 on Tuesday, reaching $89.59. 2,031,077 shares of the stock were exchanged, compared to its average volume of 2,464,807. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals has a one year low of $15.01 and a one year high of $95.49. The firm has a market capitalization of $12.62 billion, a PE ratio of -41.67 and a beta of 1.26. The company’s 50-day simple moving average is $79.26 and its two-hundred day simple moving average is $70.85.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently made changes to their positions in ARWR. Arrowstreet Capital Limited Partnership grew its holdings in Arrowhead Pharmaceuticals by 3,142.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after buying an additional 2,017,489 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after acquiring an additional 447,456 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Arrowhead Pharmaceuticals by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,353,719 shares of the biotechnology company’s stock valued at $89,873,000 after acquiring an additional 7,859 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Arrowhead Pharmaceuticals by 31.5% in the 4th quarter. Janus Henderson Group PLC now owns 1,280,446 shares of the biotechnology company’s stock valued at $84,997,000 after acquiring an additional 306,879 shares during the last quarter. Finally, Woodline Partners LP lifted its stake in Arrowhead Pharmaceuticals by 34.0% in the 3rd quarter. Woodline Partners LP now owns 1,000,158 shares of the biotechnology company’s stock worth $34,495,000 after purchasing an additional 254,002 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective on the stock. Morgan Stanley increased their price target on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Chardan Capital increased their target price on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Sanford C. Bernstein boosted their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $96.92.

View Our Latest Research Report on Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.